Assesses continuous manufacturing (CM) in pharma green transition, comparing efficiency gains with traditional production amid tech/regulatory barriers and ESG impacts.
Low- and middle-income countries (LMICs), defined by the World Bank as having a gross national income (GNI) of below $13,995, are home to nearly 80% of the global population.
This analysis reveals a paradox: 85% of APIs for U.S. branded drugs are imported (43% from Europe). Proposed tariffs threaten global supply chains, forcing pharmaceutical companies to restructure sourcing strategies.
Apeloa Pharmaceutical has released its first sustainability report. Apeloa’s 2024 Environmental, Social and Governance (ESG) report marks the start of continuous and responsible disclosure into the future.
AdvertisingEmail to: Julia.zhang@imsinoexpo.com
Media CooperationEmail to: Jennifer.Yang@imsinoexpo.com
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!